ArticleBMC cancer2025
Transcription factor FOXC2 regulates miR-145/ADAMTS5 axis to inhibit angiogenesis in hepatocellular carcinoma via circular RNA 0002898.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundCircular RNAs (circRNAs), a novel class of single-stranded, covalently closed non-coding RNA molecules, have been increasingly recognized for their roles in the cellular landscape over the past decade. These molecules are predominantly localized within the cytoplasm of eukaryotic cells and have been implicated in the pathogenesis of a spectrum of cancers. Despite this, the specific contributions of circRNAs to hepatocellular carcinoma (HCC) have yet to be fully delineated.
methodsOur research has identified that cyclic RNA0002898 is downregulated in HCC, with its reduced expression correlating with advanced tumor grade and diminished patient survival outcomes. Furthermore, we have demonstrated that the transcription factor forkhead box C2 (FOXC2) regulates the expression of cyclic RNA0002898, and diminished levels of cyclic RNA0002898 in HCC are associated with enhanced tumor cell proliferation, migration, and invasion in vitro. Mechanistic insights revealed that cyclic RNA0002898 could modulate the expression levels of the tumor suppressor a disintegrin and metalloproteinase with thrombospondin motif 5 (ADAMTS5) by antagonizing miR-145, thereby inhibiting angiogenesis and suppressing the growth of HCC cells.
resultsOur findings collectively elucidate the regulatory role, functional significance, and underlying mechanism of cyclic RNA0002898 in HCC, a previously uncharted relationship. The potential prognostic implications of cyclic RNA0002898 and its therapeutic potential as a target in HCC warrant further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.